Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Primary Central Nervous System Lymphoma
About this trial
This is an interventional treatment trial for Primary Central Nervous System Lymphoma focused on measuring Lymphoma, PCNSL, Primary CNS lymphoma
Eligibility Criteria
Inclusion Criteria: Histologically proven primary CNS lymphoma. Absence of disease outside the CNS. ECOG performance status 0-3 Negative HIV status. Peripheral blood counts with granulocytes >1.5 x 109L and platelets > 100 x 109L. Serum creatinine <150mmol/L. Serum bilirubin <1.5 times and AST <2 times upper limit of normal. Age >18 and <=70 years. Patients must give written informed consent. Corticosteroids prior to histological diagnosis are allowed. Exclusion Criteria: Previous history of malignancy (other than non-melanomatous skin carcinoma, or carcinoma in situ of cervix completely excised). Patients who are pregnant or lactating. NYHA (New York State Heart Association classification) cardiac failure grade 3 Macroscopic spinal thecal or spinal cord disease.
Sites / Locations
- The Canberra Hospital
- Calvary Mater Newcastle
- Prince of Wales Hospital
- Westmead Hospital
- Illawarra Cancer Care Centre
- Royal Brisbane Hospital
- Mater QRI
- Premion - Tugun
- Princess Alexandra Hospital
- Royal Adelaide Hospital
- Andrew Love Cancer Centre, Geelong Hospital
- Peter MacCallum Cancer Centre
- Sir Charles Gairdner Hospital
- Auckland Hospital
- Christchurch Hospital
Arms of the Study
Arm 1
Active Comparator
1